Compare stocks

Nanobiotix S.A. is a biotechnology company focusing on developing innovative nanomedicine solutions for cancer therapy. Its core business is centered around the development of NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in cancer treatment. Founded in 2003, Nanobiotix is headquartered in Paris, France. Its strategic positioning lies in its proprietary nanotechnology platform, which aims to address unmet needs in oncology by potentially improving outcomes and safety for patients undergoing radiotherapy. The company operates primarily within the European and U.S. markets, with ongoing clinical trials to expand its therapeutic applications.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.